Skip to content

About Us

Highly experienced leaders in the discovery and development of immunology drugs

LEADERSHIP

PHOTO-2020-06-17-21-26-04-raju-ventyx-ventyx1

Raju Mohan, PhD

Founder, CEO & Director
chris2-img_1339-1200w-1-ventyx-ventyx1

Chris Krueger, JD, MBA

Chief Business Officer
John3-IMG_1332-1200w-ventyx-ventyx1

John Nuss, PhD

Chief Scientific Officer
Dick-Gregg-Photo-web-1-ventyx-ventyx1

Dick Gregg, MD

Chief Medical Officer

Dick-Gregg-Photo-web-1-ventyx-ventyx1

Dick Gregg, MD

Chief Medical Officer

martin-auster2

Martin D. Auster, MD

Chief Financial Officer

Board of Directors

Jigar-Choksey

Jigar Choksey, MBA

Board of Directors
RichGaster-FINAL3-sized-ventyx-ventyx1

Richard Gaster, MD, PhD

Board of Directors
aaron-ventyx-ventyx1

Aaron Royston, MD, MBA

Board of Directors

Somu-photo-ventyx-ventyx1

Somu Subramaniam

Board of Directors
PHOTO-2020-06-17-21-26-04-raju-ventyx-ventyx1

Raju Mohan, PhD

Board of Directors

Advisory Board

William J. Sandborn, MD

Chairman, Advisory Board

Alexa Kimball, MD

Advisory Board

James G. Krueger, MD, PhD

Advisory Board

Emma Guttman-Yassky, MD, PhD

Advisory Board

Bruce Sands, MD, MS

Advisory Board

Investors

Coming soon

Raju Mohan, PhD

Founder, Chief Executive Officer & Director

Raju founded Ventyx Biosciences and has served as a member of our board of directors since the company’s inception. Prior to Ventyx, Raju founded Akarna Therapeutics, which was acquired by Allergan for up to $1.2B. In addition to Ventyx, Raju has founded Oppilan Pharma, Zomagen Biosciences and Vimalan Biosciences, all immunology-focused specialty pharmaceutical companies. From 2006 to 2011, Raju served as Vice President and head of the San Diego site for Exelixis and Vice President of Chemistry at X-Ceptor Therapeutics (acquired by Exelixis). Raju started his pharmaceutical career at Berlex Biosciences, a subsidiary of Bayer/Schering AG where he held positions of increasing responsibility. Raju is responsible for the discovery of multiple small molecule drug candidates that have entered clinical trials. He is the inventor of MINNEBRO®, an approved therapeutic for hypertension. He has published extensively in peer-reviewed journals and is an inventor on 64 issued US patents. Raju received a PhD in Chemistry from the University of Illinois and a Master’s degree from the Indian Institute of Technology.

Chris Krueger, JD, MBA

Chief Business Officer

Chris has served as our Chief Business Officer since the company’s inception. He was mostly recently the Chief Executive Officer of Oppilan Pharma and the Chief Business Officer of Zomagen Biosciences.

Chris brings more than 20 years of experience in the life science industry with operational responsibility and leadership for multiple functional areas, including business development, legal affairs, finance, alliance management and operations. Chris has negotiated a broad range of equity and debt financings, strategic partnerships, acquisitions and licensing transactions.

Previously, Chris served as an executive at Akarna Therapeutics (acquired by Allergan for up to $1.2B), Ardea Biosciences (acquired by AstraZeneca), Xencor (Nasdaq:XNCR), X-Ceptor Therapeutics (acquired by Exelixis) and Aurora Biosciences (acquired by Vertex Pharmaceuticals). Earlier in his career, he was a lawyer at Cooley LLP. Chris received a J.D. and M.B.A. in Finance from the University of Southern California and a B.A. in Economics from the University of California, San Diego.

John Nuss, PhD

Chief Scientific Officer

John brings more than 25 years of small molecule drug discovery and development experience to the company, primarily in the areas of immunology, inflammation, oncology, and metabolic disease. Prior to joining Ventyx, John was Vice President of Drug Discovery at the Ferring Research Institute where he was responsible for global drug discovery activities. John also previously served as Senior Vice President of Chemistry at Exelixis. Under his leadership, his teams have advanced more than 30 molecules into the clinic. He is the co-inventor of the approved therapeutics COMETRIQ®/CABOMETYX® and MINNEBRO®, and led the team that discovered COTELLIC®. Earlier in his career he held positions of increasing responsibility in discovery at Chiron and served as an Assistant Professor of Chemistry at the University of California, Riverside. John has more than 80 publications and 30 issued patents. He received a bachelor’s degree in chemistry from the University of Kansas, a PhD in organic chemistry from the University of Wisconsin, Madison, and was an NIH postdoctoral fellow in organic synthesis at Stanford University.

Richard Gregg, MD

Chief Medical Officer

Dick has served as our Chief Medical Officer since 2019. Prior to joining Ventyx Biosciences, Dick was Chief Scientific Officer at Vitae Pharmaceuticals, where he was responsible for all drug discovery and early development activities. Prior to Vitae, Dr. Gregg spent 19 years leading various groups at Bristol-Myers Squibb, including roles as Vice President of Clinical Discovery, where he was responsible for early clinical development, clinical pharmacology, translational medicine and biomarker technologies, and as Vice President of Metabolic and Cardiovascular Drug Discovery. Dick earned his MD from Stanford University School of Medicine, and is board certified in Internal Medicine and in Endocrinology and Metabolism.

Martin D. Auster, MD

Chief Financial Officer

Marty serves as our Chief Financial Officer. Prior to joining Ventyx, he served as Managing Director, Biotechnology Analyst at Credit Suisse. Prior to Credit Suisse, he was a senior biotechnology analyst at UBS Securities. Prior to that, he served as an executive at Ascendis Pharma and United Therapeutics. Earlier in his career, he held positions in the investment banking industry, including as a Senior Biotechnology Analyst at Wachovia Securities and a Senior Analyst/Healthcare-focused Portfolio Manager at GLG Partners. He received a B.A. from the University of Michigan and an M.D. from the University of Texas Medical Branch.

Jigar Choksey, MBA

Board of Directors

Jigar is a Principal at Third Point, a New York based asset management firm founded in 1995. At Third Point, Jigar leads investing in public and private healthcare companies. Previously, he was the healthcare sector lead and Assistant Portfolio Manager at Highline Capital. Prior to Highline, he worked at Magnetar Capital covering healthcare and as an investment banker in the M&A and Restructuring group at Evercore Partners. Jigar began his career as a management consultant at Booz & Company. He graduated magna cum laude from Northwestern University with a B.S. in Biomedical Engineering and Economics and an M.B.A. from the Wharton School at the University of Pennsylvania.

Richard Gaster, MD, PhD

Board of Directors

Rich is a Partner at venBio with experience as a physician, entrepreneur, and life science investor. He currently serves on the board of Pharvaris, Elevation Oncology, Aeovian Pharmaceuticals, NorthSea Therapeutics, Arrakis Therapeutics, Attralus, and Stargazer Pharmaceuticals and served as a board observer for Akero Therapeutics and Harmony Biosciences. Prior to joining venBio, Richard served as the head of translational medicine at Pliant Therapeutics. As a key member of the initial management team, Richard participated in the formation and launch of Pliant Therapeutics from Third Rock Ventures. During his tenure at Third Rock Ventures, Richard was responsible for company creation to transform new areas of science into innovative drug discovery companies. He began his career as a resident physician in Harvard’s Plastic and Reconstructive Surgery Program. Richard has published numerous articles in top-tier peer-reviewed journals including Nature Medicine and Nature Nanotechnology, holds more than a dozen patents, and was named one of Forbes “30 Under 30” in Science and Healthcare. Richard holds a BSE in Bioengineering from the University of Pennsylvania where he graduated summa cum laude. He received his M.D. and Ph.D. in Bioengineering from Stanford University in the Medical Scientist Training Program.

Aaron Royston, MD, MBA

Board of Directors

Aaron is a Managing Partner at venBio with a background in life science investing, healthcare strategy, and as an entrepreneur. Since joining venBio, he has been involved in launching and investing in a number of venBio companies including Apellis Pharmaceuticals (IPO 2017), Menlo Therapeutics (IPO 2018), Akero Therapeutics (IPO 2019), Harmony Biosciences (IPO 2020), RayzeBio, Artiva Biotherapeutics, Neurogastrx, Impel NeuroPharma, and Swift Health Systems.Prior to joining venBio, Dr. Royston was a member of the investment team at Vivo Capital, a life science venture capital firm. Previously, he worked at Bain & Company, where he advised biotechnology companies on a range of strategic and operational issues. Earlier in his career, he coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences. Dr. Royston received his B.S. in biological sciences from Duke University, and his M.D. and M.B.A. degrees from the University of Pennsylvania. In 2010, he was recognized by the United States White House as a Champion of Change for his work in Technology and Innovation.

Somu Subramaniam

Board of Directors

Somu Subramaniam is the co-founder and Managing Partner of New Science Ventures. Somu serves on the Board of Directors of Achronix Semiconductor Corporation, BrightVolt, Cambridge Epigenetix, Dali Wireless, Ferric, Inc, NorthSea Therapeutics, Oxyrane, ProterixBio, Ralexar Therapeutics, Resolve Therapeutics, Svelte Medical Systems, Vascular Therapies, Ventyx Biosciences, Inc and Zeotap GmbH. Somu has also served on the Boards of Dezima Pharma (acquired by Amgen), Ception Therapeutics (acquired by Cephalon), BioVex (acquired by Amgen), Lightwire (acquired by Cisco), K2M (acquired by Welsh Carson) and Akarna Therapeutics (acquired by Allergan). Prior to founding NSV, Somu was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, Somu was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group, and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee. Somu holds a B.Tech. degree from the Indian Institute of Technology and an M.B.A. from Harvard Business School.

William J. Sandborn, MD

Chairman, Advisory Board

Dr. Sandborn is a Distinguished Professor of Medicine and Chief, Division of Gastroenterology at University of California San Diego Health System. He is also the Director of the UCSD IBD Center. Dr. Sandborn was a Professor of Medicine at the Mayo Clinic in Rochester Minnesota and Vice Chairman of the Division of Gastroenterology and Hepatology. Dr. Sandborn has published over 841 peer-reviewed articles including articles in the New England Journal of Medicine, Nature, Lancet, JAMA, Annals of Internal Medicine, and Gastroenterology. In 2019 he was awarded the Sherman Prize for his work in inflammatory bowel disease. He is a co-founder of Santarus (acquired by Salix in 2013) and a co-founder of Shoreline Biosciences. Dr. Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota.

Alexa Kimball, MD

Advisory Board

Dr. Kimball is CEO and President of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, a large academic multi-specialty group that includes Harvard Medical School faculty. A Professor of Dermatology at Harvard Medical School, Dr. Kimball’s research includes psoriasis and hidradenitis suppurativa. She has published over 340 papers, conducted over 150 clinical trials, has extensive experience in drug development, and was recognized by Fierce HealthCare with a Women of Influence Award in 2020. Dr. Kimball received her MD from the Yale School of Medicine, her MPH from the Johns Hopkins Bloomberg School of Public Health, and her bachelor's degree in molecular biology and public and international affairs from Princeton University.

James G. Krueger, MD, PhD

Advisory Board

Dr. Krueger is the Director of the Milstein Medical Research Program and D. Martin Carter Professor in Clinical Investigation at Rockefeller University in New York. Dr. Krueger’s group at Rockefeller was the first to conduct clinical trials with specific, targeted immune antagonists in psoriasis. Recent focus of the Krueger group has been definition of new inflammatory pathways, as well as new types of inflammatory cells in psoriasis lesions that are now being targeted with new biologic drugs. Dr. Krueger is certified by the American Board of Dermatology. Dr. Krueger earned his PhD in virology and cell biology from the Rockefeller University. He earned an MD from Cornell University Medical College, where he also completed his internship in internal medicine and residency in dermatology.

Emma Guttman-Yassky, MD, PhD

Advisory Board

Dr. Guttman is the system chair of the department of dermatology, and the Waldman Professor of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai, New York. She is the director of the center for excellence in eczema and the laboratory for inflammatory skin diseases and current President of the international eczema council/ICE. Dr. Guttman’s major research focus areas are atopic dermatitis (AD)/eczema and alopecia areata. Her research has made paradigm-shifting discoveries on the immunologic basis of AD/eczema in both adults and children, opening the door for novel, pathway-specific drugs to treat this disease. Dr. Guttman earned her MD from Sackler School of Medicine at the Tel-Aviv University, and her PhD degree from the Bar-Ilan University, Israel.

Bruce Sands, MD, MS

Advisory Board

Bruce is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. After completing GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Dr. Sands is widely recognized for his clinical investigations of new therapeutics for the inflammatory bowel diseases and has published over 250 original manuscripts. He was the lead investigator of the landmark studies ACCENT 2, UNIFI and VARSITY, published in the New England Journal of Medicine. Dr. Sands received his BA and MD from Boston University, and trained in internal medicine at the Hospital of the University of Pennsylvania.